DBV Technologies | DBVT - Creditori Commerciali

Prezzo Delle Azioni
19.65
Cambio Giornaliero
-0.19 -0.96%
Mensile
-4.66%
Annuale
77.03%
Q2 Previsione
19.19




Creditori Commerciali Cambiamento Data
Acadia Pharmaceuticals USD 12.25M 1.34M 2026-03
Alnylam Pharmaceuticals USD 126.63M 10.91M 2026-03
Amarin USD 48.15M 2.8M 2026-03
BioCryst Pharmaceuticals USD 10.96M 4.87M 2026-03
BioMarin Pharmaceutical USD 793.15M 34.12M 2026-03
DBV Technologies USD 39.82M 972K 2025-09
Esperion Therapeutics USD 68.41M 3.34M 2026-03
Galectin Therapeutics USD 3.7M 99K 2024-06
Halozyme Therapeutics USD 14.1M 6.8M 2026-03
Incyte USD 228.62M 1.41B 2026-03
Insmed USD 73.38M 6.53M 2026-03
Ionis Pharmaceuticals USD 26.03M 2.05M 2026-03
Neurocrine Biosciences USD 691.3M 145.8M 2026-03
PTC Therapeutics USD 25.48M 20M 2026-03
Sarepta Therapeutics USD 70.38M 210.46M 2026-03
Ultragenyx Pharmaceutical USD 42M 11M 2026-03
United Therapeutics USD 498.3M 491.2M 2026-03